Dosing of subjects in the second cohort investigating a higher dose of O3R-5671 is underway. Pharmacokinetic and safety data support investigating a higher dose in the second cohort of the study, which is in progress. Preclinical data from various in vitro models demonstrate that O3R-5671 potently inhibits TNFα, IL-12, and IL-23 release and induces IL-10. Preclinical data demonstrated that O3R-5671 inhibits the release of the inflammatory cytokines TNFα and IL-23 and promotes the release of the immunomodulatory cytokine IL-10. About Onco3R TherapeuticsAt Onco3R Therapeutics, we are driven by our purpose to transform the lives of patients with autoimmune diseases and cancer through precision-designed, best-in-class therapies.